PPAR-targeted therapies in the field of NAFLD and NASH have demonstrated pleiotropic beneficial effects, both on NAFLD-specific outcomes as well as on a multitude of metabolic functions. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.